BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation, have signed a multi-year exclusive distribution agreement.

Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma surgeries.

The agreement is an important milestone in the commercialization strategy of the BonAlive granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons," said Dr Fredrik Ollila, CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone.”

Florian Kemmerich, president of Olympus Biotech International, said, "The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome."

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The focus is to provide world-leading biomaterial solutions for the treatment of chronically infected bone.

Olympus Biotech is focused on minimally-invasive regenerative therapies in bone and soft tissues and provides minimally-invasive regenerative therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting technologies as well as tools for access, placement and delivery.